Idiopathic Short Stature
📧 Sign up to get email alerts when something new happens for Idiopathic Short Stature.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow [Phase 3]
A Phase 3 trial comparing once-weekly Somapacitan to daily Norditropin in children with growth disorders (SGA, Turner syndrome, Noonan syndr…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders [Phase 3]
An ongoing Phase 3 trial compares weekly lonapegsomatropin to daily somatropin in children and adolescents with short stature due to growth …
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [Phase 2]
BioMarin is conducting a Phase 2 trial of Vosoritide in children with idiopathic short stature, and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of Inpegsomatropin injections in children with idiopathic short stature; the study…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) [Phase 1, Phase 2]
A Phase 1b/2 clinical trial evaluating GenSci134 in children with idiopathic short stature; the study is currently not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature. [Phase 3]
Phase 3 clinical trial comparing weekly somatrogon to daily Genotropin in children with Idiopathic Short Stature or Small for Gestational Ag…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
A terminated clinical trial investigating the genetic basis of how children with idiopathic short stature respond to growth hormone treatmen…
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 [Phase 3]
Phase 3 clinical trial evaluating the safety and efficacy of somapacitan for pediatric growth disorders; results have been posted for condit…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Study to Assess Growth in Children With Idiopathic Short Stature
BioMarin is recruiting for a study to assess growth in children with idiopathic short stature.
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: Skeletal Muscle Effects of GH in Boys
A completed clinical trial evaluating the effects of growth hormone on skeletal muscle in boys with growth hormone deficiency or idiopathic …
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Evolution of the Quality of Life of Short Statured Children Treated With Growth Hormone : Evaluation at Adult Size
This completed clinical trial from Assistance Publique - Hôpitaux de Paris evaluates the evolution of quality of life at adult size in child…
-
CLINICAL_TRIALS other · 2025-08-15Clinical Trial Update: A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature [Phase 2]
A study extension update for a Phase 2 trial of PEG-somatropin in children with idiopathic short stature; the trial is currently active but …
-
FDA approval · 2025-07-09FDA Approved: OMNITROPE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for OMNITROPE (somatropin) submitted by Sandoz Inc.
-
FDA approval · 2025-01-31FDA Approved: NORDITROPIN — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Norditropin (somatropin) from Novo Nordisk.
-
FDA label_change · 2024-08-16FDA Approved: GENOTROPIN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Genotropin (somatropin) from Pfizer, resulting in changes to the labeling. The notice reflects t…
-
CLINICAL_TRIALS trial_result · 2024-01-24Clinical Trial Update: A Trial of YPEG-rhGH in Children With Short Stature [Phase 2]
Phase 2 trial update for YPEG-rhGH in children with short stature, including idiopathic short stature and small for gestational age conditio…
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height [Phase 4]
Phase 4 trial update evaluating combination therapy of Growth Hormone and GnRH agonist in children with idiopathic short stature.
-
CLINICAL_TRIALS trial_result · 2020-12-14Clinical Trial Update: Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin [Phase 2]
Phase 2 trial update evaluating growth response to somatropin in children with idiopathic short stature.
-
FDA approval · 2020-01-08FDA Approved: GENOTROPIN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved Genotropin (somatropin) via a supplemental application submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS withdrawal · 2019-08-05Clinical Trial Update: Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF) [Phase 4]
Phase 4 trial evaluating IGF-1 generation test as predictor for growth response to GH treatment in idiopathic short stature has been withdra…
-
CLINICAL_TRIALS trial_result · 2018-08-17Clinical Trial Update: Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS [Phase 3]
Phase 3 clinical trial update evaluating efficacy and safety of rhGH (Jintropin) in pediatric participants with idiopathic short stature (IS…
-
CLINICAL_TRIALS trial_result · 2018-06-07Clinical Trial Update: Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature [Phase 3]
A Phase 3 trial evaluating aromatase inhibitors alone and with growth hormone in adolescent boys with idiopathic short stature has completed…
-
FDA approval · 2018-01-30FDA Approved: ZOMACTON — Supplemental Application (Ferring Pharmaceuticals Inc.)
FDA approved a supplemental application for ZOMACTON (somatropin) by Ferring Pharmaceuticals. The action updates the product's indications o…
-
CLINICAL_TRIALS trial_result · 2017-12-20Clinical Trial Update: Short Stature Related Distress [Phase 4]
A Phase 4 clinical trial investigating short stature related distress in idiopathic short stature and self-image issues has completed.
-
CLINICAL_TRIALS research · 2017-07-19Clinical Trial Update: A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature [Phase 2]
A Phase 2 clinical trial evaluating PEG-somatropin for treating children with idiopathic short stature.